Table 2.
Cortical Bone Parameters of the Femoral Midshaft of EGFR Inhibitor–Treated Mice Measured by pQCT
| MC | Erlotinib | T80 | Gefitinib | |
|---|---|---|---|---|
| Cortical BMD (mg/cm3) | 1002.2 ± 10.2 | 985.9 ± 13.3 | 1008.9 ± 8.1 | 964.8 ± 10.1a |
| Cortical area (mm2) | 0.79 ± 0.01 | 0.76 ± 0.02 | 0.78 ± 0.02 | 0.72 ± 0.03 |
| Cortical thickness (mm) | 0.179 ± 1.3 | 0.176 ± 0.002 | 0.177 ± 0.003 | 0.163 ± 0.003a |
| Periosteal perimeter (mm) | 4.88 ± 0.04 | 4.76 ± 0.06 | 4.82 ± 0.07 | 4.79 ± 0.08 |
| Endosteal perimeter (mm) | 3.50 ± 0.04 | 3.41 ± 0.04 | 3.44 ± 0.06 | 3.54 ± 0.06 |
MC = vehicle control for erlotinib treatment; Erlotinib = 50 mg/kg/day; T80 = vehicle control for gefitinib treatment; Gefitinib = 100 mg/kg/day.
a
p < .05 versus corresponding vehicle.